Diabete Mellitus
119
17
25
42
Key Insights
Highlights
Success Rate
98% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.8%
1 terminated out of 119 trials
97.7%
+11.1% vs benchmark
8%
9 trials in Phase 3/4
2%
1 of 42 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 42 completed trials
Clinical Trials (119)
Assessing the Effectiveness of Large Language Model (LLM)-Enabled Nurse Treatment Planning in 2 Indian Districts
Inflammation and Diabetes: Evaluating Antioxidant Levels
Nephroprotective Effects of Fig (Ficus Carica L.) Leaf Supplementation
Amelioration of Lipid Profile Through Date Cider-vinegar Along With 5:2 Intermittent Fasting
Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy
The Effect of SPU on Hormonal and Cardiometabolic Factors
Effect of Curd Cheese on Metabolic Health in Adults
Faisalabad Initiative of Research and Management of NCDs
Impact of Pilates Exercises on Diabetic Erectile Dysfunction.
Duodenal pulsENDO as an Early Treatment for Type 2 DM
To Assess the Prevalence, Management Practices, and Clinical Outcomes Associated With Hyperglycemia Among Hospitalized Patients, With a Particular Focus on the Interplay Between Metabolic Biomarkers, Nutritional Status, and Body Composition
Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity
Oral Health and Systemic Diseases: Survey of General Practitioners
Clinical Information System Impact on Hospitalized Patients With Chronic Disease
CGM Experience, Preferences & Blood Glucose Parameters
The Role Intraoperative Salbutamol Inhaler in Preventing Atelectasis
Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3
Study of the Safety and Efficacy of Pancreatic Endocrine Cells in Adult Patients With Type 1 Diabetes
Choices and Experiences Around Closed-loop Therapy in Type 1 Diabetes
Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal Bevacizumab